Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial
Authors
Kulke, MHorsch, D
Caplin, M
Anthony, L
Bergsland, E
Oberg, K
Welin, S
Warner, R
Lombard-Bohas, C
Kunz, P
Grande, E
Valle, Juan W
Fleming, D
Lapuerta, P
Banks, P
Jackson, S
Wheeler, D
Zambrowicz, B
Sands, A
Pavel, M
Affiliation
Dana-Farber Cancer Institute, Boston, MassIssue Date
2016